| Document |
Document Title |
|
WO/2023/244669A1 |
There is a tremendous need for advanced human model systems to screen new immunomodulatory candidates in an economical and robust manner, which is addressed by the present disclosure. Compositions and methods are provided for in vitro im...
|
|
WO/2023/243120A1 |
[Problem] To provide a novel peptide having a BMP4 binding ability. [Solution] The present invention pertains to a peptide and a peptide-containing agent. The peptide according to the present invention has an amino acid sequence of E-R-V...
|
|
WO/2023/241492A1 |
The present invention relates to a VHH antibody that specifically binds to human CD318 or an antigen-binding fragment thereof, a preparation method therefor, and a use thereof. Provided are a CD318 binding molecule comprising an anti-CD3...
|
|
WO/2023/243709A1 |
Provided are a method and a living cell freezing system for freezing an unfrozen specimen comprising living cells in such a manner as to keep the cells alive. The method comprises: causing an unfrozen specimen to reach a frozen state by ...
|
|
WO/2023/241538A1 |
This disclosure provides an anti-SIGLEC15 antibody, antigen-binding fragment, and the use thereof.
|
|
WO/2023/243727A1 |
The purpose of the present invention is to provide a preservative composition which is used in place of or in combination with a cell-penetrating substance such as DMSO that has been commonly used in a culture medium for cryopreservation...
|
|
WO/2023/243627A1 |
The present invention provides a thymic epithelial cell production method, the method including a step for culturing thymic epithelial progenitor cells for a long period of time. The present invention also provides a transplant therapeut...
|
|
WO/2023/241522A1 |
Provided are a T cell receptor targeting a KRAS G12V mutant polypeptide and a use thereof. The T cell receptor molecule specifically targets a KRAS G12V mutation; a CDR3 sequence of an α chain variable domain thereof contains CAVRDIEGAG...
|
|
WO/2023/244846A1 |
Proteins are important dietary nutrients. They serve as a fuel source or as sources of amino acids, including the essential amino acids that cannot be synthesized by the body, as well as to build muscle mass and improve performance. The ...
|
|
WO/2023/242783A1 |
The present disclosure relates to methods of producing an enveloped virus in a suspension cell culture, the method comprising culturing a suspension cell line expressing a tetracycline-suppressible gene expression system in a cell cultur...
|
|
WO/2022/216514A9 |
Provided are methods for generating γδ T cells from induced pluripotent stem cells. Also provided are genetically engineered iPSCs, γδ T cells, CAR- γδ T cells, and methods of using the same.
|
|
WO/2023/243679A1 |
The problem addressed by the present invention is to provide a viral vector with a higher infectious titer for application to gene and cell therapies. The present invention relates to a method for producing a viral vector that includes...
|
|
WO/2023/244470A1 |
ROS signal upregulates surface CALR and promotes macrophage-HSC interactions, safeguarding the development of stem cells that are stressed or damaged. Described herein are methods of controlling hematopoiesis, e.g., reducing hematopoiesi...
|
|
WO/2023/241610A1 |
Provided is an adenovirus packaging and production cell line, a construction method therefor and a use thereof. Compared with traditional HEK293 cells, the adenovirus packaging and production cell line solves the problem of generation of...
|
|
WO/2023/244547A1 |
Antibodies with improved affinity for integrin avB8 and uses thereof are provided.
|
|
WO/2023/245108A2 |
Compositions and methods for reducing MHC class I protein expression in a cell comprising genetically modifying MHC class I for use e.g., in adoptive cell transfer therapies.
|
|
WO/2023/242434A1 |
Modified immune cells expressing a heterodimeric gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) are described. The disclosed modified immune cells enhance expression of CARs. Also disclosed are compositions and m...
|
|
WO/2023/039447A9 |
The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems fo...
|
|
WO/2023/242426A1 |
This invention relates to a method for expanding immune cells, the method comprising co-culturing the immune cells and at least one epithelial organoid, wherein the epithelial organoid comprises more epithelial cells than mesenchymal cel...
|
|
WO/2023/241496A1 |
Provided in the present invention are a composition for promoting the migration, homing and implantation of hematopoietic stem progenitor cells and the use thereof. The composition contains a corticotropin-releasing hormone. The composit...
|
|
WO/2023/243097A1 |
Provided are a live cell freezing system and a method for freezing live cells that includes cooling an unfrozen sample that contains a freezing solution containing a cryoprotectant and live cells that are immersed in the freezing solutio...
|
|
WO/2023/242230A1 |
Provided herein are cell-based meat compositions suitable for consumption comprising cells harvested from suspension cell culture and comprising an emulsion mixture. Also provide here are methods of making a cell-based meat composition s...
|
|
WO/2023/242346A1 |
The invention provides a heart tissue model comprising a heart tissue with at least one inner cavity or a central chamber, wherein the heart tissue model comprises at least two different heart tissues selected from left ventricle tissue,...
|
|
WO/2023/245186A1 |
Described herein are methods for making edible fat product using insect cells. The methods include isolating a population of insect cells, which may be precursor cells, seeding the population of insect cells onto a scaffold, and contacti...
|
|
WO/2023/241567A1 |
Provided is a precursor plasmid used for preparing a screening-tag-free plasmid, the precursor plasmid comprising: (1) a conditioned replication initiation site having a plasmid replication initiation capacity that is dependent on regula...
|
|
WO/2023/241669A1 |
Provided are a CRISPR-Cas effector protein, a gene editing system therefor, and an application. The CRISPR-Cas effector protein comprises a protein which is at least 70% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to...
|
|
WO/2023/245004A1 |
This disclosure relates to methods of inducing insulin production from pancreatic duct cells in response to glucose or transdifferentiating pancreatic duct cells into insulin-producing beta-like cells by administering an agent that inhib...
|
|
WO/2023/238877A1 |
Provided is a model cell for fatty liver or an insulin-resistant disease state, the model cell comprising a hepatic cell derived from a non-human animal in which at least 70% of the liver is replaced by human hepatic cells.
|
|
WO/2023/239736A1 |
Provided herein is a recombinant cell comprising a deletion of a gene encoding a transporter associated with antigen processing (TAP) protein and mutations in the CD3 epsilon gene and an HLA-A gene. Also provided are systems and methods ...
|
|
WO/2023/239048A1 |
The present invention relates to a method for preparing pancreatic cancer organoids mimicking a cancer microenvironment. In addition, the present invention relates to a method for evaluating the efficacy of pancreatic cancer organoids pr...
|
|
WO/2023/236889A1 |
The present application relates to a multi-specific binding molecule targeting BCMA, GPRC5D and T cell receptors. Specifically, the present application discloses a BCMA-GPRC5D-CD3 multi-specific antibody, which can activate T cells while...
|
|
WO/2023/236991A1 |
The present invention relates to a trispecific antibody targeting HER2, PD-L1 and VEGF. The trispecific antibody comprises two identical first polypeptides and two identical second polypeptides, wherein 1) each first polypeptide comprise...
|
|
WO/2023/237541A1 |
We identified several novel δΤ-cell and γΤ-cell receptor chains mediating anti-tumour or anti-infective responses as well as methods for identifying same.
|
|
WO/2023/238910A1 |
The present invention provides a skin health condition improving agent characterized by containing a sterol ester that is obtained from rice bran.
|
|
WO/2023/239640A1 |
A biopolymer-based tissue scaffold on which stem cells, muscle cells, or cultivated meat are growable can include at least one protein, at least one starch, at least one polysaccharide, and at least one crosslinking agent. The protein, t...
|
|
WO/2023/238837A1 |
Provided are an exosome complex capable of achieving higher therapeutic effects than conventional products, and a manufacturing method thereof. This exosome complex contains an exosome and affinity molecules for a target cell, said aff...
|
|
WO/2023/240182A1 |
The application provides modified immune effector cells wherein a Lysine Demethylase 4A (KDM4A) gene or gene product is modified in the cell so that the expression and/or function of KDM4A in the cell is reduced or eliminated. The applic...
|
|
WO/2023/240169A1 |
Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and a membrane bound IL-12 and methods of making and using the same. Also provided are c...
|
|
WO/2023/236330A1 |
Provided are a cancer vaccine based on antigen-presenting cell membrane components, a method for preparing same, and use thereof. The cancer vaccine comprises one of the following: (1) a nanovesicle prepared from cell membrane components...
|
|
WO/2023/239609A1 |
Methods and compositions are described herein that can modify, inhibit, and/or delete at least one Satb2 allele or inhibit expression of a Satb2 gene in cells in vivo or in vitro.
|
|
WO/2023/238949A1 |
This vector set is introduced into host cells, and cells for producing heteromultimeric proteins are selected from the host cells into which the vector set is introduced. The vector set is a set of a first expression vector and a second ...
|
|
WO/2023/236891A1 |
The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, pharmaceutical composition comprising the same and the uses thereof.
|
|
WO/2023/236760A1 |
Disclosed herein are a printing apparatus matched with a microfluidic chip and a printing method. A printing head comprises: a printing channel configured for outputting particles and a specific liquid, and an auxiliary channel located o...
|
|
WO/2023/240069A1 |
Disclosed herein are compositions comprising mesenchymal stromal cell-derived extracellular vesicle-associated miRNAs (MSC-EV-miRNAs) and their use in subjects diagnosed with acute respiratory distress syndrome (ARDS) and other inflammat...
|
|
WO/2023/237663A1 |
Uses of Tregs, in particular CAR-Tregs represent a very promising approach for inducing and maintaining tolerance. However, Tregs could lose Treg identity in an inflammatory environment. There is thus a great deal at stake to "lock" Treg...
|
|
WO/2023/236796A1 |
Provided are a CD79b humanized antibody-based chimeric antigen receptor and use thereof. The present disclosure relates to a CD79b humanized antibody -based chimeric antigen receptor, which includes an antigen binding domain, a transmemb...
|
|
WO/2023/240242A1 |
A method of automated cell culturing and characterization can include regulating one or more parameters of an ambient environment within an environmentally isolated, airtight enclosure. A biological specimen can be cultured within the en...
|
|
WO/2023/240282A1 |
Provided are compositions and methods for a cell population comprising engineered stem cells comprising a synthetic cytokine receptor for a non-physiological ligand. The non-physiological ligand activates the synthetic cytokine receptor ...
|
|
WO/2023/235928A1 |
Disclosed herein is a method of identifying an arrhythmogenic pluripotent stem cell-derived cardiomyocyte (PSC-CM), the method comprising: (i) determining whether CD200 is expressed on a surface of the PSC-CM; wherein if CD200 is express...
|
|
WO/2023/238932A1 |
The present invention addresses the problem of providing a method and a reagent for detecting undifferentiated pluripotent stem cells. Said problem is solved by being able to detect few remaining undifferentiated pluripotent stem cells b...
|
